Vimarsana
Biggest News Aggregation in the World

Page 18 - Genentech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genentech Today - Breaking & Trending Today

Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs - Vimarsana News

Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs

Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.

Source: ajmc.com
The beauty of biology - Vimarsana News

The beauty of biology

MIT biology student Hanjun Lee had planned to pursue chemistry at MIT. A course in genetics changed that, noting, “There’s a beauty in studying and finding the patterns in nature.”

Source: mit.edu
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity - Vimarsana News

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% At week 24, 100% of CT-388...

OBD and King's College London collaborate on RA | Company Announcement - Vimarsana News

OBD and King's College London collaborate on RA | Company Announcement

Investegate announcements from OBD and King's College London collaborate on RA

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript - Vimarsana News

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript

Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller.